Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.

Dabbs DJ, Chivukula M, Carter G, Bhargava R.

Mod Pathol. 2006 Nov;19(11):1506-11. Epub 2006 Aug 25.

2.
3.

Morphologic, molecular and microenvironment factors associated with stromal invasion in breast ductal carcinoma in situ: Role of myoepithelial cells.

Aguiar FN, Cirqueira CS, Bacchi CE, Carvalho FM.

Breast Dis. 2015;35(4):249-52. doi: 10.3233/BD-150416.

PMID:
26397772
4.

P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.

Paredes J, Lopes N, Milanezi F, Schmitt FC.

Virchows Arch. 2007 Jan;450(1):73-80. Epub 2006 Nov 23.

PMID:
17123107
5.

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM.

Mod Pathol. 2006 Feb;19(2):264-71.

7.

Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast.

Grenier J, Soria JC, Mathieu MC, Andre F, Abdelmoula S, Velasco V, Morat L, Besse B, Dunant A, Spielmann M, Delaloge S.

Anticancer Res. 2007 Jan-Feb;27(1B):547-55.

8.

Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.

Nassar A, Sussman ZM, Lawson D, Cohen C.

Breast J. 2012 Sep;18(5):399-405. doi: 10.1111/j.1524-4741.2012.01279.x. Epub 2012 Aug 10.

PMID:
22882580
9.

Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.

Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N.

Am J Surg Pathol. 2008 Apr;32(4):544-52. doi: 10.1097/PAS.0b013e31815a87e2.

PMID:
18300793
10.

Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.

Merkin RD, Vanner EA, Romeiser JL, Shroyer ALW, Escobar-Hoyos LF, Li J, Powers RS, Burke S, Shroyer KR.

Hum Pathol. 2017 Apr;62:23-32. doi: 10.1016/j.humpath.2016.10.006. Epub 2016 Nov 2.

PMID:
27816721
11.

Metaplastic breast carcinomas and their relationship with basal-like phenotype.

Cakir A, Gönül II, Uluoğlu O.

Turk Patoloji Derg. 2012;28(2):134-41. doi: 10.5146/tjpath.2012.01112.

12.

Phenotypic and Functional Characterization of Ductal Carcinoma In Situ-Associated Myoepithelial Cells.

Rohilla M, Bal A, Singh G, Joshi K.

Clin Breast Cancer. 2015 Oct;15(5):335-42. doi: 10.1016/j.clbc.2015.01.004. Epub 2015 Jan 21.

PMID:
25700939
13.

[Morphological features of basal-like subtype invasive carcinoma of breast].

Gao LX, Yang GZ, Ding HY, Li L.

Zhonghua Bing Li Xue Za Zhi. 2008 Feb;37(2):83-7. Chinese.

PMID:
18681317
15.

Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship.

Thike AA, Iqbal J, Cheok PY, Tse GM, Tan PH.

J Clin Pathol. 2013 Aug;66(8):665-70. doi: 10.1136/jclinpath-2012-201428. Epub 2013 Mar 28.

PMID:
23539741
16.

Basal-like immunophenotype markers and prognosis in early breast cancer.

Cassol L, Silveira Graudenz M, Zelmanowicz A, Cancela A, Werutsky G, Rovere RK, Garicochea B.

Tumori. 2010 Nov-Dec;96(6):966-70.

17.

Molecular phenotypes of DCIS predict overall and invasive recurrence.

Williams KE, Barnes NL, Cramer A, Johnson R, Cheema K, Morris J, Howe M, Bundred NJ.

Ann Oncol. 2015 May;26(5):1019-25. doi: 10.1093/annonc/mdv062. Epub 2015 Feb 12.

PMID:
25678586
18.

Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer.

Sasa M, Bando Y, Takahashi M, Hirose T, Nagao T.

J Surg Oncol. 2008 Jan 1;97(1):30-4.

PMID:
17929254
19.

[Basal-like breast cancers: clinicopathological features and outcome].

De Brot M, Soares FA, Stiepcich MM, Cúrcio VS, Gobbi H.

Rev Assoc Med Bras (1992). 2009 Sep-Oct;55(5):529-34. Portuguese.

20.

HER2 as a prognostic factor in breast cancer.

Ménard S, Fortis S, Castiglioni F, Agresti R, Balsari A.

Oncology. 2001;61 Suppl 2:67-72. Review.

PMID:
11694790

Supplemental Content

Support Center